Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

The combined effect of modern highly active antiretroviral therapy regimens and adherence on mortality over time.

Lima VD, Harrigan R, Bangsberg DR, Hogg RS, Gross R, Yip B, Montaner JS.

J Acquir Immune Defic Syndr. 2009 Apr 15;50(5):529-36. doi: 10.1097/QAI.0b013e31819675e9.

2.

Increased resilience to the development of drug resistance with modern boosted protease inhibitor-based highly active antiretroviral therapy.

Lima VD, Gill VS, Yip B, Hogg RS, Montaner JS, Harrigan PR.

J Infect Dis. 2008 Jul 1;198(1):51-8. doi: 10.1086/588675.

PMID:
18498238
3.

Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

Van Vaerenbergh K.

Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Review.

PMID:
11813503
4.

Adherence, virological and immunological outcomes for HIV-infected veterans starting combination antiretroviral therapies.

Braithwaite RS, Kozal MJ, Chang CC, Roberts MS, Fultz SL, Goetz MB, Gibert C, Rodriguez-Barradas M, Mole L, Justice AC.

AIDS. 2007 Jul 31;21(12):1579-89.

5.

Simpler regimens may enhance adherence to antiretrovirals in HIV-infected patients.

Maggiolo F, Ripamonti D, Arici C, Gregis G, Quinzan G, Camacho GA, Ravasio L, Suter F.

HIV Clin Trials. 2002 Sep-Oct;3(5):371-8.

PMID:
12407486
6.
7.
8.
9.

Treatment limitations imposed by antiretroviral drug resistance mutations: implication for choices of first line regimens in resource-limited settings.

Mtambo A, Chan K, Shen A, Lima V, Hogg R, Montaner J, Moore D.

HIV Med. 2012 Mar;13(3):141-7. doi: 10.1111/j.1468-1293.2011.00950.x. Epub 2011 Nov 22.

11.

Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naïve Patients.

d'Arminio Monforte A, Lepri AC, Rezza G, Pezzotti P, Antinori A, Phillips AN, Angarano G, Colangeli V, De Luca A, Ippolito G, Caggese L, Soscia F, Filice G, Gritti F, Narciso P, Tirelli U, Moroni M.

AIDS. 2000 Mar 31;14(5):499-507.

PMID:
10780712
12.
13.

Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes.

Nachega JB, Hislop M, Dowdy DW, Chaisson RE, Regensberg L, Maartens G.

Ann Intern Med. 2007 Apr 17;146(8):564-73.

PMID:
17438315
14.

Predictors of virologic failure in HIV-1-infected patients starting highly active antiretroviral therapy in Porto Alegre, Brazil.

Tuboi SH, Harrison LH, Sprinz E, Albernaz RK, Schechter M.

J Acquir Immune Defic Syndr. 2005 Nov 1;40(3):324-8.

PMID:
16249707
15.
16.

The nucleoside backbone affects durability of efavirenz- or nevirapine-based highly active antiretroviral therapy in antiretroviral-naive individuals.

Annan NT, Nelson M, Mandalia S, Bower M, Gazzard BG, Stebbing J.

J Acquir Immune Defic Syndr. 2009 Jun 1;51(2):140-6. doi: 10.1097/QAI.0b013e3181a56e81.

PMID:
19352201
17.

Optimal timing and best antiretroviral regimen in treatment-naive HIV-infected individuals with advanced disease.

Manzardo C, Zaccarelli M, Agüero F, Antinori A, Miró JM.

J Acquir Immune Defic Syndr. 2007 Sep;46 Suppl 1:S9-18. Review.

PMID:
17713424
18.

Immune Reconstitution in Severely Immunosuppressed Antiretroviral-Naive HIV-1-Infected Patients Starting Efavirenz, Lopinavir-Ritonavir, or Atazanavir-Ritonavir Plus Tenofovir/Emtricitabine: Final 48-Week Results (The Advanz-3 Trial).

Miro JM, Manzardo C, Ferrer E, Loncà M, Guardo AC, Podzamczer D, Domingo P, Curran A, Clotet B, Cruceta A, Lozano F, Pérez I, Plana M, Gatell JM; Advanz-3 Study Group.

J Acquir Immune Defic Syndr. 2015 Jun 1;69(2):206-15. doi: 10.1097/QAI.0000000000000567.

PMID:
25831464
19.

Lipid profiles for antiretroviral-naive patients starting PI- and NNRTI-based therapy in the Swiss HIV cohort study.

Young J, Weber R, Rickenbach M, Furrer H, Bernasconi E, Hirschel B, Tarr PE, Vernazza P, Battegay M, Bucher HC.

Antivir Ther. 2005;10(5):585-91.

PMID:
16152752
20.

Comparison of single and boosted protease inhibitor versus nonnucleoside reverse transcriptase inhibitor-containing cART regimens in antiretroviral-naïve patients starting cART after January 1, 2000.

Mocroft, Horban, Clumeck, Stellbrink, Monforte dA, Zilmer, Kirk, Gatell, Phillips, Lundgren; EuroSIDA Study Group.

HIV Clin Trials. 2006 Nov-Dec;7(6):271-84.

PMID:
17208897

Supplemental Content

Support Center